Unique ID issued by UMIN | UMIN000001612 |
---|---|
Receipt number | R000001939 |
Scientific Title | Sonazoid Enhanced LivEr Cancer Trial for Early Detection |
Date of disclosure of the study information | 2009/01/01 |
Last modified on | 2020/01/09 10:44:39 |
Sonazoid Enhanced LivEr Cancer
Trial for Early Detection
SELECTED Study
Sonazoid Enhanced LivEr Cancer
Trial for Early Detection
SELECTED Study
Japan |
Hepatitis B virus or Hepatitis C virus related liver cirrhosis
Hepato-biliary-pancreatic medicine |
Malignancy
NO
To prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for hepatitis virus related cirrhosis, who are defined as super high-risk patients for hepatocarcinogenesis.
Furthermore, to analyze whether early detection of HCC by CE-US has a survival benefit than that by B-mode US.
Efficacy
Size of HCC which is detected first
1) Time to detection of HCC
2) Number of HCC which is detected first
3) Stage of HCC which is detected first
4) The ability of definitive diagnosis of HCC
5) Sensitivity, Specificity and accuracy of the diagnosis of HCC
6) The improvement of prognosis of patients who are diagnosed in this study
7) The accumulated rate of detection of HCC
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Diagnosis
Medicine | Maneuver |
<Group of CE-US>
screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
<Group of B-mode US>
screening by conventional B-mode US every 3-5 months
20 | years-old | <= |
Not applicable |
Male and Female
1) Age over 20
2) HBV or HCV related liver cirrhosis
3) No history of HCC
4) Diagnosed as liver cirrhosis histologically or clinically
Histologically confirmed by liver biopsy
Confirmed by formula of diagnosing cirrhosis
Radiological finding
Finding of portal hypertension
Platelet<130,000
5) Inpatient or outpatient
6) Patients who signed a written informed consent form
1) History of hypersensitivity to egg yolk
2) Pregnant or lactating women and women who may be pregnant
3) Severe liver dysfunction(AST, ALT,or BIL level >10ULN
4) Associated with HCC
5) Paients receiving interferon
6) Age under 20
7) Judged by investigator not to be appropriate for inclusion in this study
760
1st name | |
Middle name | |
Last name | Masatoshi Kudo |
Kinki University School of Medicine
Gastroenterology and Hepatology
377-2, Oono-Higashi, Osaka-Sayama, Osaka, Japan
072-366-0221
1st name | |
Middle name | |
Last name | Kazuomi Ueshima |
Kinki University School of Medicine
Gastroenterology and Hepatology
377-2, Oono-Higashi, Osaka-Sayama, Osaka, Japan
072-366-0221
kaz-ues@med.kindai.ac.jp
Japan Liver Oncology Group (JLOG)
Japan Liver Oncology Group (JLOG)
Non profit foundation
NO
2009 | Year | 01 | Month | 01 | Day |
Published
https://www.karger.com/Article/FullText/501082
656
2019 | Year | 06 | Month | 06 | Day |
Main results already published
2008 | Year | 10 | Month | 10 | Day |
2008 | Year | 11 | Month | 17 | Day |
2009 | Year | 01 | Month | 01 | Day |
2019 | Year | 12 | Month | 01 | Day |
2009 | Year | 01 | Month | 01 | Day |
2020 | Year | 01 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001939
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |